Generali Asset Management SPA SGR Purchases Shares of 12,755 McKesson Co. (NYSE:MCK)

Generali Asset Management SPA SGR purchased a new position in shares of McKesson Co. (NYSE:MCK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,755 shares of the company's stock, valued at approximately $7,269,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cibc World Market Inc. increased its holdings in McKesson by 6.3% during the 4th quarter. Cibc World Market Inc. now owns 20,252 shares of the company's stock worth $11,542,000 after purchasing an additional 1,207 shares during the period. Commerce Bank increased its stake in shares of McKesson by 2.0% during the third quarter. Commerce Bank now owns 156,781 shares of the company's stock worth $77,516,000 after buying an additional 3,020 shares during the period. West Oak Capital LLC increased its stake in shares of McKesson by 867.7% during the fourth quarter. West Oak Capital LLC now owns 3,000 shares of the company's stock worth $1,710,000 after buying an additional 2,690 shares during the period. Brentview Investment Management LLC acquired a new stake in McKesson in the fourth quarter valued at approximately $3,018,000. Finally, Ingalls & Snyder LLC lifted its stake in McKesson by 8.2% in the fourth quarter. Ingalls & Snyder LLC now owns 13,824 shares of the company's stock worth $7,878,000 after acquiring an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company's stock.

McKesson Stock Performance

McKesson stock traded down $6.91 during midday trading on Friday, hitting $659.45. 1,969,537 shares of the company's stock were exchanged, compared to its average volume of 800,864. The firm's 50 day simple moving average is $616.14 and its 200 day simple moving average is $574.33. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $670.79. The stock has a market cap of $82.65 billion, a price-to-earnings ratio of 30.19, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52.

Remove Ads

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. On average, equities research analysts forecast that McKesson Co. will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be given a $0.71 dividend. The ex-dividend date is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.43%. McKesson's dividend payout ratio (DPR) is 13.00%.

Wall Street Analyst Weigh In

MCK has been the topic of a number of analyst reports. Citigroup reduced their price objective on shares of McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Bank of America cut their price target on McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. Morgan Stanley upped their price objective on McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. Evercore ISI raised their target price on McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, Mizuho started coverage on McKesson in a report on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target for the company. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $649.36.

Insider Buying and Selling at McKesson

In related news, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. The trade was a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $600.66, for a total value of $5,382,514.26. Following the completion of the transaction, the chief executive officer now owns 69,625 shares of the company's stock, valued at $41,820,952.50. The trade was a 11.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is owned by company insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.